tirzepatide age approval Join a Trial Testing in Adolescents Big update in pediatric diabetes

It also fuels cellular energy production and promotes a healthy cardiovascular system

By activating both incretin pathways simultaneously, tirzepatide enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetitemechanisms that collectively improve glycaemic control and promote weight loss

Why community doses are lower: No FDA approval means conservative self-titration

However, many post-bariatric patients tolerate GLP-1 therapy well, especially when doses are titrated carefully and monitored by experienced providers

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, administered as a once-weekly subcutaneous injection for obesity and type 2 diabetes

Articles that were not within the scope of the study, non-English papers, and those without translations were excluded